Developer docs
API playgroundTry for free, no card

Search company profiles

ALTATHERA Pharmaceuticals

Full company profile

uuid0002iev

Namestring
ALTATHERA Pharmaceuticals
Legal namestring
AltaThera Pharmaceuticals, LLC
Websiteurl
altathera.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

AltaThera Pharmaceuticals is a Chicago-based, privately held hospital specialty pharmaceutical company founded in 2009 that develops and commercializes intravenous cardiovascular therapies for cardiac arrhythmias. Its sole commercial product, Sotalol IV (sotalol hydrochloride injection, 10 mL vial at 15 mg/mL), is an FDA-approved intravenous antiarrhythmic indicated for adult and pediatric patients with life-threatening ventricular arrhythmias and atrial fibrillation/atrial flutter. Sotalol IV was one of the first drugs approved (March 2020) under the FDA's Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program, in which the company used proprietary pharmacometric PK/PD modeling — rather than traditional clinical trials — to support regulatory submissions. The technology platform spans dosing optimization, pediatric extrapolation, QT-interval safety prediction, and pipeline development, and is applied across the full drug lifecycle.

The company's business model is the direct commercialization of a single prescription pharmaceutical product to hospital systems in the United States. AltaThera employs a field sales organization led by a VP of Sales, engages GPOs and IDNs for formulary inclusion, and operates an HCP ordering portal at sotaloliv.com, supported by a customer service line, a medical information hotline, and a market access team handling coding, billing, and reimbursement inquiries. Customers are hospital electrophysiology specialists, pediatric cardiology programs, and hospital pharmacy/procurement teams. Pricing is not publicly disclosed; economics flow through negotiated hospital and GPO contracts. The company has a senior leadership team spanning commercial pharma, pediatric and adult electrophysiology, and corporate finance, and is actively pursuing label and pipeline expansion in pediatric and congenital heart disease indications.

Short descriptiontext

AltaThera Pharmaceuticals is a Chicago-based hospital specialty pharmaceutical company that develops and commercializes Sotalol IV, an FDA-approved intravenous antiarrhythmic developed via pharmacometric PK/PD modeling. It serves U.S. electrophysiology specialists, pediatric cardiologists, and hospital systems treating adult and pediatric cardiac arrhythmias.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intravenous antiarrhythmic drugs, cardiac arrhythmia therapeutics, hospital specialty pharmaceuticals, model-informed drug development, pharmacometric PK/PD modeling
Industry2 codes
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Antiarrhythmic Hospital Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Sotalol IV Product Sales
TypeHardware Sales
Description

AltaThera commercializes Sotalol IV (sotalol hydrochloride injection) as a hospital-use pharmaceutical product. Revenue is generated through product sales to hospitals and healthcare systems. US healthcare professionals can order via sotaloliv.com. The company also earns from product training and workflow integration support services to hospital accounts.

altathera.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Sotalol IV (sotalol hydrochloride injection, 10 mL vial, 15 mg/mL) — prescription pharmaceutical product with no public list price
ModelOtherBilling cadencePay-as-you-go
Notes

Prescription pharmaceutical product sold to hospitals and healthcare providers. No public pricing listed. Ordering available via sotaloliv.com and customer service at 312-445-8900.

altathera.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Sotalol IV
Description

Sotalol IV (sotalol hydrochloride injection) is an FDA-approved intravenous antiarrhythmic indicated for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation/flutter patients, for both adult and pediatric populations.

altathera.com
Core offering1 text field

AltaThera Pharmaceuticals develops and commercializes Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter in adult and pediatric patients. The product is developed through a proprietary Model-Informed Drug Development (MIDD) platform using pharmacometric PK/PD modeling, enabling rapid therapeutic assessment (1-hour IV loading) and shorter hospital stays (outpatient discharge in under 24 hours for appropriate patients).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Mean length of stay reduced to 0.8 days with Sotalol IV vs. 3.6 days for oral sotalol (PEAKS Registry, 151 patients)
+3 more records
Product overview1 text field

AltaThera Pharmaceuticals operates as a single-product company focused on Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic therapy. The company develops and commercializes hospital-use intravenous therapies for cardiovascular treatment. Sotalol IV is the core and only commercial product, designed for adult and pediatric patients with cardiac arrhythmias including atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. The product enables rapid intravenous drug initiation, allowing faster therapeutic assessment and shorter hospital stays compared to traditional oral sotalol loading protocols.

Product and service1 record
1Sotalol IV (sotalol hydrochloride injection)
CategoryAntiarrhythmic Pharmaceuticals
Description

FDA-approved intravenous antiarrhythmic (10 mL vial, 15 mg/mL) indicated for adult and pediatric patients for the treatment of life-threatening ventricular arrhythmias (including sustained ventricular tachycardia) and for the maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter. Enables rapid therapeutic assessment with maximum serum concentration reached in 1 hour and potential outpatient discharge in under 24 hours for adult patients with adequate renal function. Sold to hospitals and healthcare systems via direct sales and the sotaloliv.com HCP portal.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1U.S. Food and Drug Administration (FDA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

AltaThera was among the first pharmaceutical companies to participate in the FDA's MIDD (Model-Informed Drug Development) Paired Meeting Pilot Program. The FDA collaborated with AltaThera to review MIDD modeling data as the basis for Sotalol IV's 2020 approval — one of the first drugs approved under this regulatory pathway, using modeling rather than traditional clinical trials.

altathera.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-03-28
Description

AltaThera partnered with Rush University Medical Center to support arrhythmia research internationally. Through a charitable donation of IV Sotalol (sotalol hydrochloride injection 15mg/mL), AltaThera supported research on prophylaxis for post-operative dysrhythmias conducted at Hanoi Heart Hospital in Hanoi, Vietnam over 2019-2020.

3University of Pennsylvania (Veterinary Program)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2019-01-15
Description

AltaThera donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to support research into heart arrhythmias in dogs, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxers. Professor Anna Gelzer conducted electrophysiologic studies to test IV sotalol's ability to suppress arrhythmia inducibility.

altathera.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty cardiology pharmaceutical company developing acute cardiovascular therapies (Etripamil nasal spray for PSVT). Comparable in target market (hospital/EP specialists) and business model (specialty pharma focused on acute arrhythmia management).

TypeDirect peer
Description

Clinical-stage company developing an inhaled antiarrhythmic for atrial fibrillation. Comparable as a direct competitive antiarrhythmic development focused on acute arrhythmia management in cardiology.

TypeBroad incumbent
Description

Specialty pharmaceutical company with a focus on injectable and hospital-based therapeutics, including cardiovascular products. Comparable in hospital-channel distribution and specialty injectable orientation, though broader in therapeutic areas.

TypeBroad incumbent
Description

Specialty pharmaceutical company focused on injectable and hospital-administered products, including cardiovascular injectables. Comparable in targeting hospital channels with differentiated injectable formulations.

TypeBroad incumbent
Description

Specialty injectable pharmaceutical company with a portfolio including cardiovascular and critical care injectables. Comparable in hospital-channel injectable focus and pursuit of differentiated formulations of off-patent molecules.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with a sizable injectable portfolio including cardiovascular hospital products. Comparable in hospital injectable channel and emphasis on reformulated/generic specialty injectables.

TypeBroad incumbent
Description

Largest pharmaceutical company with established IV antiarrhythmic and cardiovascular hospital products (e.g., various IV cardiovascular therapeutics). Comparable via overlapping cardiovascular hospital channel and ownership of competing/similar assets.

TypeBroad incumbent
Description

Global pharmaceutical company with extensive generic injectable portfolio including cardiovascular products. Comparable in producing generic injectable formulations of off-patent molecules for hospital use.

TypeBroad incumbent
Description

Global pharmaceutical company with a large generic injectable portfolio including cardiovascular products. Comparable in distributing generic injectable formulations used in hospital settings.

TypeOthers
Description

Cardiology/metabolic specialty pharmaceutical company. Comparable as a small-cap specialty pharma with cardiovascular focus, though addressing different therapeutic indications (e.g., heart failure).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ALTATHERA Pharmaceuticals

Antiarrhythmic Hospital Pharmaceuticalsaltathera.com

AltaThera Pharmaceuticals is a Chicago-based hospital specialty pharmaceutical company that develops and commercializes Sotalol IV, an FDA-approved intravenous antiarrhythmic developed via pharmacometric PK/PD modeling. It serves U.S. electrophysiology specialists, pediatric cardiologists, and hospital systems treating adult and pediatric cardiac arrhythmias.

What ALTATHERA Pharmaceuticals does

AltaThera Pharmaceuticals is a Chicago-based, privately held hospital specialty pharmaceutical company founded in 2009 that develops and commercializes intravenous cardiovascular therapies for cardiac arrhythmias. Its sole commercial product, Sotalol IV (sotalol hydrochloride injection, 10 mL vial at 15 mg/mL), is an FDA-approved intravenous antiarrhythmic indicated for adult and pediatric patients with life-threatening ventricular arrhythmias and atrial fibrillation/atrial flutter. Sotalol IV was one of the first drugs approved (March 2020) under the FDA's Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program, in which the company used proprietary pharmacometric PK/PD modeling — rather than traditional clinical trials — to support regulatory submissions. The technology platform spans dosing optimization, pediatric extrapolation, QT-interval safety prediction, and pipeline development, and is applied across the full drug lifecycle.

The company's business model is the direct commercialization of a single prescription pharmaceutical product to hospital systems in the United States. AltaThera employs a field sales organization led by a VP of Sales, engages GPOs and IDNs for formulary inclusion, and operates an HCP ordering portal at sotaloliv.com, supported by a customer service line, a medical information hotline, and a market access team handling coding, billing, and reimbursement inquiries. Customers are hospital electrophysiology specialists, pediatric cardiology programs, and hospital pharmacy/procurement teams. Pricing is not publicly disclosed; economics flow through negotiated hospital and GPO contracts. The company has a senior leadership team spanning commercial pharma, pediatric and adult electrophysiology, and corporate finance, and is actively pursuing label and pipeline expansion in pediatric and congenital heart disease indications.

ALTATHERA Pharmaceuticals firmographics

Firmographics
Name
ALTATHERA Pharmaceuticals
Legal name
AltaThera Pharmaceuticals, LLC
Website
https://altathera.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
AltaThera Pharmaceuticals is a Chicago-based hospital specialty pharmaceutical company that develops and commercializes Sotalol IV, an FDA-approved intravenous antiarrhythmic developed via pharmacometric PK/PD modeling. It serves U.S. electrophysiology specialists, pediatric cardiologists, and hospital systems treating adult and pediatric cardiac arrhythmias.
Ownership category
akta.pro rank

ALTATHERA Pharmaceuticals industry classification

Industry
Product category
Antiarrhythmic Hospital Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
SECONDARYHLAIALAG
Clinical Pharmacology & Pharmacometrics (Modeling & Simulation)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Intravenous antiarrhythmic drugs
  • Cardiac arrhythmia therapeutics
  • Hospital specialty pharmaceuticals
  • Model-informed drug development
  • Pharmacometric PK/PD modeling

Where ALTATHERA Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ALTATHERA Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Sotalol IV Product Sales: AltaThera commercializes Sotalol IV (sotalol hydrochloride injection) as a hospital-use pharmaceutical product. Revenue is generated through product sales to hospitals and healthcare systems. US healthcare professionals can order via sotaloliv.com. The company also earns from product training and workflow integration support services to hospital accounts.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSotalol IV (sotalol hydrochloride injection, 10 mL vial, 15 mg/mL) — prescription pharmaceutical product with no public list price

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

ALTATHERA Pharmaceuticals product offering

Product offering

Core offering

AltaThera Pharmaceuticals develops and commercializes Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter in adult and pediatric patients. The product is developed through a proprietary Model-Informed Drug Development (MIDD) platform using pharmacometric PK/PD modeling, enabling rapid therapeutic assessment (1-hour IV loading) and shorter hospital stays (outpatient discharge in under 24 hours for appropriate patients).

Product overview

AltaThera Pharmaceuticals operates as a single-product company focused on Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic therapy. The company develops and commercializes hospital-use intravenous therapies for cardiovascular treatment. Sotalol IV is the core and only commercial product, designed for adult and pediatric patients with cardiac arrhythmias including atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. The product enables rapid intravenous drug initiation, allowing faster therapeutic assessment and shorter hospital stays compared to traditional oral sotalol loading protocols.

Differentiator

Problem solved

Functional benefit

Brands

  • Sotalol IV: Sotalol IV (sotalol hydrochloride injection) is an FDA-approved intravenous antiarrhythmic indicated for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation/flutter patients, for both adult and pediatric populations.

Products and services

  • Sotalol IV (sotalol hydrochloride injection) FDA-approved intravenous antiarrhythmic (10 mL vial, 15 mg/mL) indicated for adult and pediatric patients for the treatment of life-threatening ventricular arrhythmias (including sustained ventricular tachycardia) and for the maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter. Enables rapid therapeutic assessment with maximum serum concentration reached in 1 hour and potential outpatient discharge in under 24 hours for adult patients with adequate renal function. Sold to hospitals and healthcare systems via direct sales and the sotaloliv.com HCP portal.

Quantifiable outcome

  • Mean length of stay reduced to 0.8 days with Sotalol IV vs. 3.6 days for oral sotalol (PEAKS Registry, 151 patients)
  • +3 more outcomes

Companies that use ALTATHERA Pharmaceuticals

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

ALTATHERA Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ALTATHERA Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • U.S. Food and Drug Administration (FDA)coreStrategic or Co-development Partner · 1 January 2020AltaThera was among the first pharmaceutical companies to participate in the FDA's MIDD (Model-Informed Drug Development) Paired Meeting Pilot Program. The FDA collaborated with AltaThera to review MIDD modeling data as the basis for Sotalol IV's 2020 approval — one of the first drugs approved under this regulatory pathway, using modeling rather than traditional clinical trials.
  • Rush University Medical CenterminorStrategic or Co-development Partner · 28 March 2019AltaThera partnered with Rush University Medical Center to support arrhythmia research internationally. Through a charitable donation of IV Sotalol (sotalol hydrochloride injection 15mg/mL), AltaThera supported research on prophylaxis for post-operative dysrhythmias conducted at Hanoi Heart Hospital in Hanoi, Vietnam over 2019-2020.
  • University of Pennsylvania (Veterinary Program)minorStrategic or Co-development Partner · 15 January 2019AltaThera donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to support research into heart arrhythmias in dogs, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxers. Professor Anna Gelzer conducted electrophysiologic studies to test IV sotalol's ability to suppress arrhythmia inducibility.

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

ALTATHERA Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Milestone Pharmaceuticals: Specialty cardiology pharmaceutical company developing acute cardiovascular therapies (Etripamil nasal spray for PSVT). Comparable in target market (hospital/EP specialists) and business model (specialty pharma focused on acute arrhythmia management).
  • InCarda Therapeutics: Clinical-stage company developing an inhaled antiarrhythmic for atrial fibrillation. Comparable as a direct competitive antiarrhythmic development focused on acute arrhythmia management in cardiology.

Broad incumbents

  • ANI Pharmaceuticals: Specialty pharmaceutical company with a focus on injectable and hospital-based therapeutics, including cardiovascular products. Comparable in hospital-channel distribution and specialty injectable orientation, though broader in therapeutic areas.
  • Eagle Pharmaceuticals: Specialty pharmaceutical company focused on injectable and hospital-administered products, including cardiovascular injectables. Comparable in targeting hospital channels with differentiated injectable formulations.
  • Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company with a portfolio including cardiovascular and critical care injectables. Comparable in hospital-channel injectable focus and pursuit of differentiated formulations of off-patent molecules.
  • Hikma Pharmaceuticals: Global specialty pharmaceutical company with a sizable injectable portfolio including cardiovascular hospital products. Comparable in hospital injectable channel and emphasis on reformulated/generic specialty injectables.
  • Pfizer: Largest pharmaceutical company with established IV antiarrhythmic and cardiovascular hospital products (e.g., various IV cardiovascular therapeutics). Comparable via overlapping cardiovascular hospital channel and ownership of competing/similar assets.
  • Viatris: Global pharmaceutical company with extensive generic injectable portfolio including cardiovascular products. Comparable in producing generic injectable formulations of off-patent molecules for hospital use.
  • Teva Pharmaceuticals: Global pharmaceutical company with a large generic injectable portfolio including cardiovascular products. Comparable in distributing generic injectable formulations used in hospital settings.

Others

  • Lexicon Pharmaceuticals: Cardiology/metabolic specialty pharmaceutical company. Comparable as a small-cap specialty pharma with cardiovascular focus, though addressing different therapeutic indications (e.g., heart failure).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ALTATHERA Pharmaceuticals social profiles

Digital presence

ALTATHERA Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ALTATHERA Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

ALTATHERA Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ALTATHERA Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALTATHERA Pharmaceuticals

What does ALTATHERA Pharmaceuticals do?

AltaThera Pharmaceuticals develops and commercializes Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter in adult and pediatric patients. The product is developed through a proprietary Model-Informed Drug Development (MIDD) platform using pharmacometric PK/PD modeling, enabling rapid therapeutic assessment (1-hour IV loading) and shorter hospital stays (outpatient discharge in under 24 hours for appropriate patients).

Is ALTATHERA Pharmaceuticals a public or private company?

ALTATHERA Pharmaceuticals is a private company. It is classified as unknown and is currently operating.

When was ALTATHERA Pharmaceuticals founded?

ALTATHERA Pharmaceuticals was founded in 2009. It employs 11 to 50 people.

Where is ALTATHERA Pharmaceuticals based?

ALTATHERA Pharmaceuticals is headquartered in Chicago, United States, in the North America region.

How does ALTATHERA Pharmaceuticals make money?

One revenue line is on record: sotalol IV Product Sales.

Who are ALTATHERA Pharmaceuticals's main competitors?

Direct peers on record are Milestone Pharmaceuticals and InCarda Therapeutics. Broad incumbents are ANI Pharmaceuticals, Eagle Pharmaceuticals, Amphastar Pharmaceuticals, Hikma Pharmaceuticals, Pfizer, Viatris and Teva Pharmaceuticals. Lexicon Pharmaceuticals is listed as an others.

Does ALTATHERA Pharmaceuticals have an API?

No public API is recorded for ALTATHERA Pharmaceuticals.

What industry is ALTATHERA Pharmaceuticals in?

ALTATHERA Pharmaceuticals's product category is Antiarrhythmic Hospital Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizAltaThera Pharmaceuticals Appoints Dr. Jim Perry as Pediatric Chief Medical OfficerAltaThera Pharmaceuticals has appointed Dr. Jim Perry as Pediatric Chief Medical Officer. Dr. Perry brings over 30 years of experience in pediatric cardiology and electrophysiology, having previously led programs at Yale University and founded the pediatric electrophysiology program at Rady Children's Hospital San Diego. He will focus on advancing the company's Sotalol IV offering for pediatric electrophysiology specialists and congenital heart disease programs.Business Wire BlogAltaThera Pharmaceuticals Names Dr. Jim Perry as Pediatric Chief Medical OfficerAltaThera Pharmaceuticals announced the appointment of Dr. Jim Perry as Pediatric Chief Medical Officer. Dr. Perry brings over 30 years of experience as a pediatric cardiologist and electrophysiologist, having founded the pediatric electrophysiology program at Rady Children's Hospital San Diego and served as Chief of Pediatric Cardiology at Yale University. The appointment is intended to advance the company's Sotalol IV offering for pediatric electrophysiology specialists and congenital heart disease programs.BioSpaceAltaThera Pharmaceuticals Names Dr. Jim Perry as Pediatric Chief Medical OfficerAltaThera Pharmaceuticals has appointed Dr. Jim Perry as its Pediatric Chief Medical Officer to advance education, accessibility, and clinical integration of the company's Sotalol IV offering for pediatric electrophysiology specialists. Dr. Perry brings over 30 years of experience in pediatric cardiology and electrophysiology, having founded the pediatric electrophysiology program at Rady Children's Hospital San Diego and previously served as Chief of Pediatric Cardiology at Yale University. The appointment is intended to expand the company's footprint in pediatric cardiology care.Castle PlacementTop 10 Pharma Drug Discovery and Delivery Capital Raises in the U.S.This article reports on ten capital raising and M&A transactions in the U.S. pharmaceutical sector between September 1st and 15th, 2025. Key events include Bausch Health Companies' acquisition of Durect for $56.072 million and AlthaThera Pharmaceuticals receiving development capital to serve pediatric cardiac patients.GlobeNewswireHyloris reports results for the full year 2021Hyloris reported 2021 revenues of €3.1 million, up from €0.2 million in 2020, driven by out-licensing of Maxigesic IV and AltaThera royalties. The company added four new product candidates and expects to bring at least four more in 2022. It holds €50 million in cash and cash equivalents.PR NewswireAltaThera Pharmaceuticals Announces FDA Approval for New Indications of Sotalol IV: A New and Faster Way to Initiate Sotalol Therapy for Atrial Fibrillation (AFib) PatientsAltaThera Pharmaceuticals announced FDA approval for new indications of Sotalol IV, enabling 1-day hospital outpatient initiation of atrial fibrillation (AFib) therapy instead of the previous standard 3-day hospital stay. The approval, based on the FDA's Model-Informed Drug Development (MIDD) pathway, represents one of the first drugs reviewed under this new regulatory program. The company plans a commercial launch in the second half of the year, with potential benefits including reduced hospital costs and improved patient satisfaction.